|
1
|
Gill S, Thomas RR and Goldberg RM: Review
article: colorectal cancer chemotherapy. Aliment Pharmacol Ther.
18:683–692. 2003. View Article : Google Scholar
|
|
2
|
Kalady MF, Dejulius KL, Sanchez JA, et al:
BRAF mutations in colorectal cancer are associated with distinct
clinical characteristics and worse prognosis. Dis Colon Rectum.
55:128–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldberg RM, Sargent DJ, Morton RF, et al:
A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar
|
|
4
|
Medinger M, Steinbild S and Mross K:
Adjuvant and palliative anticancer treatment of colon carcinoma in
2004. Praxis (Bern 1994). 93:1633–1644. 2004.(In German).
|
|
5
|
Köhne CH: Palliative therapy of colorectal
cancer. Onkologie. 26(Suppl 7): 41–47. 2003.(In German).
|
|
6
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tournigand C, André T, Achille E, et al:
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: a randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goto S, Shirotani N, Hatakeyama M, et al:
Clinical benefit of non-toxic therapy in patients with advanced
cancer (opinion). Anticancer Res. 22:2461–2464. 2002.PubMed/NCBI
|
|
9
|
Gattinoni L, Powell DJ, Rosenberg SA and
Restifo NP: Adoptive immunotherapy for cancer: building on success.
Nat Rev Immunol. 6:383–393. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
zum Büschenfelde CM, Hermann C, Schmidt B,
Peschel C and Bernhard H: Antihuman epidermal growth factor
receptor 2 (HER2) monoclonal antibody trastuzumab enhances
cytolytic activity of class I-restricted HER2-specific T
lymphocytes against HER2-overexpressing tumor cells. Cancer Res.
62:2244–2247. 2002.
|
|
11
|
Terunuma H, Deng X, Dewan Z, Fujimoto S
and Yamamoto N: Potential role of NK cells in the induction of
immune responses: implications for NK cell-based immunotherapy for
cancers and viral infections. Int Rev Immunol. 27:93–110. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smyth MJ, Hayakawa Y, Takeda K and Yagita
H: New aspects of natural-killer-cell surveillance and therapy of
cancer. Nat Rev Cancer. 2:850–861. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hsu KC and Dupont B: Natural killer cell
receptors: regulating innate immune responses to hematologic
malignancy. Semin Hematol. 42:91–103. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kiessling R, Klein E and Wigzell H:
‘Natural’ killer cells in the mouse. I. Cytotoxic cells with
specificity for mouse Moloney leukemia cells Specificity and
distribution according to genotype. Eur J Immunol. 5:112–117.
1975.
|
|
15
|
Kärre K, Ljunggren HG, Piontek G and
Kiessling R: Selective rejection of H-2-deficient lymphoma variants
suggests alternative immune defence strategy. Nature. 319:675–678.
1986.
|
|
16
|
Ruggeri L, Capanni M, Urbani E, et al:
Effectiveness of donor natural killer cell alloreactivity in
mismatched hematopoietic transplants. Science. 295:2097–2100. 2002.
View Article : Google Scholar
|
|
17
|
Takada M, Terunuma H, Deng X, et al:
Refractory lung metastasis from breast cancer treated with
multidisciplinary therapy including an immunological approach.
Breast Cancer. 18:64–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cui Z, Willingham MC, Hicks AM, et al:
Spontaneous regression of advanced cancer: identification of a
unique genetically determined, age-dependent trait in mice. Proc
Natl Acad Sci USA. 100:6682–6687. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hicks AM, Riedlinger G, Willingham MC, et
al: Transferable anticancer innate immunity in spontaneous
regression/complete resistance mice. Proc Natl Acad Sci USA.
103:7753–7758. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gumperz JE and Parham P: The enigma of the
natural killer cell. Nature. 378:245–248. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hercend T, Farace F, Baume D, Charpentier
F, Droz JP, Triebel F and Escudier B: Immunotherapy with
lymphokine-activated natural killer cells and recombinant
interleukin-2: a feasibility trial in metastatic renal cell
carcinoma. J Biol Response Mod. 9:546–555. 1990.PubMed/NCBI
|
|
22
|
Rabinowich H, Sedlmayr P, Herberman RB and
Whiteside TL: Increased proliferation, lytic activity, and purity
of human natural killer cells cocultured with mitogen-activated
feeder cells. Cell Immunol. 135:454–470. 1991. View Article : Google Scholar
|
|
23
|
Harada H, Saijo K, Watanabe S, Tsuboi K,
Nose T, Ishiwata I and Ohno T: Selective expansion of human natural
killer cells from peripheral blood mononuclear cells by the cell
line, HFWT. Jpn J Cancer Res. 93:313–319. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Coca S, Perez-Piqueras J, Martinez D, et
al: The prognostic significance of intratumoral natural killer
cells in patients with colorectal carcinoma. Cancer. 79:2320–2328.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stinchcombe JC and Griffiths GM: Secretory
mechanisms in cell-mediated cytotoxicity. Annu Rev Cell Dev Biol.
23:495–517. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
DiLillo DJ, Yanaba K and Tedder TF: B
cells are required for optimal CD4+ and CD8+ T cell tumor immunity:
therapeutic B cell depletion enhances B16 melanoma growth in mice.
J Immunol. 184:4006–4016. 2010.
|
|
27
|
Naito Y, Saito K, Shiiba K, Ohuchi A,
Saigenji K, Nagura H and Ohtani H: CD8+ T cells infiltrated within
cancer cell nests as a prognostic factor in human colorectal
cancer. Cancer Res. 58:3491–3494. 1998.
|
|
28
|
Yu P and Fu YX: Tumor-infiltrating T
lymphocytes: friends or foes? Lab Invest. 86:231–245. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Todaro M, D’Asaro M, Caccamo N, et al:
Efficient killing of human colon cancer stem cells by gammadelta T
lymphocytes. J Immunol. 182:7287–7296. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ogino S, Nosho K, Irahara N, et al:
Lymphocytic reaction to colorectal cancer is associated with longer
survival, independent of lymph node count, microsatellite
instability, and CpG island methylator phenotype. Clin Cancer Res.
15:6412–6420. 2009. View Article : Google Scholar
|
|
31
|
Fridman WH, Pagès F, Sautès-Fridman C and
Galon J: The immune contexture in human tumours: impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pagès F, Kirilovsky A, Mlecnik B, et al:
In situ cytotoxic and memory T cells predict outcome in patients
with early-stage colorectal cancer. J Clin Oncol. 27:5944–5951.
2009.PubMed/NCBI
|
|
33
|
Sun JC and Bevan MJ: Defective CD8 T cell
memory following acute infection without CD4 T cell help. Science.
300:339–342. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fehniger TA, Bluman EM, Porter MM, et al:
Potential mechanisms of human natural killer cell expansion in vivo
during low-dose IL-2 therapy. J Clin Invest. 106:117–124. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rosenberg SA, Lotze MT, Yang JC, et al:
Combination therapy with interleukin-2 and alpha-interferon for the
treatment of patients with advanced cancer. J Clin Oncol.
7:1863–1874. 1989.PubMed/NCBI
|
|
36
|
Atzpodien J, Kirchner H, Hänninen EL,
Deckert M, Fenner M and Poliwoda H: Interleukin-2 in combination
with interferon-alpha and 5-fluorouracil for metastatic renal cell
cancer. Eur J Cancer. 29A(Suppl 5): S6–S8. 1993. View Article : Google Scholar : PubMed/NCBI
|
